MedTrace Logo

SUBLOCADE Rapid Initiation Study

NCT03993392 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-03-25

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.

Conditions

  • Opioid-use Disorder

Interventions

DRUG

TM buprenorphine

4mg TM buprenorphine, investigator choice as to brand

DRUG

SUBLOCADE

300mg subcutaneous injection

Sponsors & Collaborators

  • Indivior Inc.

    lead INDUSTRY

Principal Investigators

  • Howard Hassman · Hassman Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-29
Primary Completion
2019-12-26
Completion
2019-12-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03993392 on ClinicalTrials.gov